Suppliers / Aurobindo Pharma

Aurobindo Pharma

India AUROPHARMA.BO 4 duplicate records merged Updated 9 July 2026

Aurobindo Pharma is an API and finished-dose manufacturer based in India. It appears in 1,315 regulatory filings across 21 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, NMRC (NA) and DAV (Vietnam). Its GMP standing is certified by EMA, EAEU_EEC and US FDA, among 7 authorities. Its most recent recorded inspection, by US FDA, closed on 14 November 2025 as OAI. Customs aggregates show $265K of exports covering 18 molecules to 6 destinations in 2025.

0
active US DMFs
0
valid CEPs
12
registered plants 7 with an FDA FEI number
1,315
filings across 21 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
7 of 7 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 14 November 2025 OAI US FDA
  • 5 September 2025 OAI US FDA
  • 3 May 2024 OAI US FDA
  • 2 February 2024 OAI US FDA
  • 29 September 2023 VAI US FDA
  • 26 July 2023 NAI US FDA
  • 21 July 2023 VAI US FDA
  • 9 March 2023 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hyderabad, India Not on file
MEDAK DISTRICT, India Not on file
Anakapalli, India Not on file
Medchal, India 3004021229
Mahabubnagar, India 3007373532
Sangareddy, India 3004021263

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Alendronic Acid SFDA (Saudi Arabia) 1
Alfuzosin SFDA (Saudi Arabia) 1
Atomoxetine SFDA (Saudi Arabia) 1
Clopidogrel SFDA (Saudi Arabia) 1
Eletriptan SFDA (Saudi Arabia) 1
Finasteride SFDA (Saudi Arabia) 1
Mirtazapine SFDA (Saudi Arabia) 1
Rosuvastatin SFDA (Saudi Arabia) 1
Sitagliptin SFDA (Saudi Arabia) 1
Tadalafil SFDA (Saudi Arabia) 1
Show all 11 molecules on file
Valganciclovir SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Abacavir finished dose Alendronic Acid API Amoxicillin finished dose Bisoprolol finished dose Cephalexin finished dose Chlorpromazine finished dose Dolutegravir finished dose Doxazosin finished dose Dutasteride finished dose Ertapenem finished dose Escitalopram finished dose Finasteride API
Show 23 more molecule pages
Ibandronic Acid finished dose Lamivudine finished dose Lisinopril finished dose Meloxicam finished dose Mirtazapine API Montelukast finished dose Nicotine finished dose Permethrin finished dose Prednisone finished dose Ribavirin finished dose Sertraline finished dose Simvastatin finished dose Sotalol finished dose Telmisartan finished dose Tenofovir Disoproxil finished dose Terbinafine finished dose Tizanidine finished dose Vigabatrin finished dose Zolmitriptan finished dose Rosuvastatin API Clopidogrel API Sitagliptin API Tadalafil API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 630 3
NMRC (NA) 143 None
DAV (Vietnam) 137 None
TMDA (TZ) 115 None
EFDA (ET) 98 None
DH (HK) 39 None
EMA None 14
EAEU_EEC None 3
ANVISA (Brazil) None 2
NAFDAC (NG) None 2
FDA (GH) None 1
MHRA (UK) None 1

Scale

Year Revenue Exports Destinations
2025 $3.7B $265K 6
2024 $3.5B Not reported Not reported
2023 $3.0B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Aurobindo Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was OAI, on 14 November 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts
Company filings
Revenue as reported